Cheng Tzu-Hao, Hsu Po-Kuei, Li Anna Fen-Yau, Hung I-Chun, Huang Min-Hsiung, Hsu Han-Shui
Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei, Taiwan, ROC.
J Cancer Res Clin Oncol. 2009 Nov;135(11):1577-82. doi: 10.1007/s00432-009-0605-5. Epub 2009 Jun 2.
To determine the interrelationships of p53, MDM2, and p14(ARF) protein expression in primary esophageal squamous cell carcinoma (ESCC) and their prognostic value in ESCC.
In total, 119 patients treated for ESCC with esophagectomy were enrolled in this study. Demographic and clinical data including gender, age, depth of tumor invasion, lymph node involvement, and 5-year survival rate were collected by chart review. p53, MDM2, and p14(ARF) were detected immunohistochemically in the resected tumors to evaluate their usefulness as biomarkers of clinical outcome.
p53, MDM2, and p14(ARF) were expressed in 61 (51.3%), 34 (28.6%), and 22 (18.5%) of 119 tumor specimens, respectively. Overall, p53 protein expression was positively correlated with MDM2 (P = 0.024) and p14(ARF) expression (P = 0.026). In addition, p14(ARF) expression was most often found in specimens that were positive for both p53 and MDM2. Changes in the p53, MDM2, and p14(ARF) protein levels were not correlated with 5-year survival rate.
Expression of p53 protein correlates with increased MDM2 and p14(ARF) protein levels in ESCC. In addition, status of p53 (wild-type versus mutant) rather than expression level of p53, MDM2, or p14(ARF) is likely to be the more critical determinant of clinical outcome.
确定原发性食管鳞状细胞癌（ESCC）中p53、MDM2和p14（ARF）蛋白表达之间的相互关系及其在ESCC中的预后价值。
本研究共纳入119例行食管癌切除术治疗的ESCC患者。通过查阅病历收集人口统计学和临床数据，包括性别、年龄、肿瘤浸润深度、淋巴结受累情况和5年生存率。对切除的肿瘤进行免疫组织化学检测p53、MDM2和p14（ARF），以评估它们作为临床结局生物标志物的效用。
在119个肿瘤标本中，p53、MDM2和p14（ARF）的表达分别为61例（51.3%）、34例（28.6%）和22例（18.5%）。总体而言，p53蛋白表达与MDM2（P = 0.024）和p14（ARF）表达（P = 0.026）呈正相关。此外，p14（ARF）表达最常见于p53和MDM2均为阳性的标本中。p53、MDM2和p14（ARF）蛋白水平的变化与5年生存率无关。
ESCC中p53蛋白表达与MDM2和p14（ARF）蛋白水平升高相关。此外，p53的状态（野生型与突变型）而非p53、MDM2或p14（ARF）的表达水平可能是临床结局更关键的决定因素。
